US Patents
Patent Link |
Title |
Experimental Data |
| 6,630,160 | Process to modulate disease risk with doses of a nutraceutical | |
| 5,939,072 | Herbal composition and method of treating viral infection of the liver | Viral Infection |
| 3,980,776 | Composition containing double stranded RNA from basidiomycetes and method of use | Anti Viral |
NIH - Clinical Trial Data
Conclusions are provided for convenience. Please use the link to review article abstracts.
| Study Link | Clinical Study Conclusions |
| deVere 2002 | The endpoint for the trial was the lowering of the PSA levels. RESULTS: Of the 62 men enrolled in the study, 61 were assessable. At 4 months, 1 patient withdrew because of unrelated surgery and 7 withdrew because of disease progression; none had responded with a decrease of greater than 50% in the PSA level. By 6 months, a total of 23 patients had progression and none had responded. Thirty-eight patients had stable PSA levels after 6 months. Although not the primary endpoint of the study, in other studies these patients could have been included as responders. When the patients' rates of PSA rise before study entry were analyzed, 4 (7%) had stabilized disease while taking SME. Thus, the final results for our study patients were 0 with a complete response, 0 with a partial response, 4 (7%) with stable disease, and 23 of 61 with progression while taking SME. CONCLUSIONS: SME alone is ineffective in the treatment of clinical prostate cancer. |
| Gordon 1998 | A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial. Results were inconclusive. Significant side effects in some cases. There was an apparent tendency to increase CD4 cells. |
| Gordon 1995 | This study was carried out to assess the safety and efficacy of a combination of lentinan, an immune modulator, and didanosine (ddI) in a controlled study in HIV positive patients with CD4 levels of 200-500 cells/mm3. Didanosine was administered to HIV patients at doses of 400 mg/day (po) for six weeks (bid), then 2 mg of lentinan i.v. was added per week for 24-80 weeks. A control group (20%) received ddI only. A total of 107 patients were enrolled at three sites, and 88 patients started the ddI/lentinan phase. The combination caused significant increases in CD4 levels up to 38 weeks, whereas ddI alone was significant at the 5% level at 14 weeks. Based on these data, lentinan qualifies as a participant in future multi-drug studies in HIV. |